User:DrSteveEllis/sandbox
| Rank 2012 | Company | Country | Market Cap in 2012 (USD millions) | Market Cap in 2011 (USD billions) | % Change over year (Q2-Q2) | Website |
|---|---|---|---|---|---|---|
| 1 | Novo Nordisk | Denmark | 76.92 | 60.09 | 28.0% | novonordisk.com |
| 2 | Amgen | USA | 60.09 | 49.72 | 20.9% | amgen.com |
| 3 | Gilead Sciences | USA | 40.16 | 32.68 | 28.5% | gilead.com |
| 4 | Biogen Idec | USA | 34.26 | 25.6 | 28.5% | biogenidec.com |
| 5 | Teva Pharmaceutical Industries | Israel | 34.23 | 42.96 | -20.3% | tevapharm.com |
| 6 | Baxter International | USA | 32.27 | 33.36 | -3.3% | baxter.com |
| 7 | Celgene | USA | 28.38 | 27.52 | 3.1% | celgene.com |
| 8 | Merck KGaA | Germany | 21.16 | 20.14 | 5.1% | merckgroup.com |
| 9 | CSL | Australia | 21.11 | 18.33 | 15.2% | csl.com.au |
| 10 | Alexion Pharmaceuticals | USA | 18.85 | 10.48 | 79.9% | alxn.com |
| 11 | Vertex Pharmaceuticals | USA | 10.64 | 10.79 | -1.4% | vrtx.com |
| 12 | Regeneron | USA | 11.3 | 5.09 | 122.0% | regeneron.com |
| 13 | Forest Laboratories | USA | 8.87 | 9.09 | -2.4% | frx.com |
| 14 | UCB | Belgium | 8.77 | 6.84 | 28.2% | ucb.com |
| 15 | Élan | Ireland | 8.63 | 6.67 | 29.4% | elan.com |
| 16 | BioMarin Pharmaceutical | USA | 5.35 | 3.32 | 61.1% | biomarinpharm.com |
| 17 | Dr. Reddy's Laboratories | India | 5.35 | 5.03 | 6.4% | drreddys.com |
| 18 | Amylin Pharmaceuticals | USA | 5.06 | 1.74 | 190.8% § | amylin.com |
| 19 | Onyx Pharmaceuticals | USA | 5.06 | 2.1 | 141.0% | onyx.com |
| 20 | Actelion | Switzerland | 4.65 | 5.02 | -7.4% | actelion.com |
| 21 | Warner Chilcott | Ireland | 4.49 | 5.69 | -21.1% | wcrx.com |
| 22 | Ranbaxy Laboratories | India | 3.71 | 4.08 | -9.1% | ranbaxy.com |
| 23 | Medivation | USA | 3.65 | 0.683 | 433.4% | medivation.com |
| 24 | ARIAD Pharmaceuticals | USA | 3.18 | 1.58 | 101.3% | ariad.com |
| 25 | Seattle Genetics | USA | 2.92 | 1.89 | 54.5% | seagen.com |
§ - Acquired by Bristol-Myers Squibb in a $7 billion deal completed Aug 8 2012.
NOTE: Market Cap is an indication of the perceived value of the company (&/or its technology) and not necessarily a measure of its size, sales or number of employees; it is indicative of both current and future scale and profitability of the company. The year-on-year change in its value is indicative of the (real or perceived) performance or progress of that company over that year.